Number of pages: 100 | Report Format: PDF | Published date: 27 February, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market size value in 2021 |
US$ 1503.3 million |
Revenue forecast in 2030 |
US$ 2672.1 million |
Growth Rate |
CAGR of 6.6% from 2022 to 2030 |
Base year for estimation |
2021 |
Forecast Period |
2022-2030 |
Historical Year |
2020 |
Segments Covered |
Treatment Type, Route of administration, Distribution Channel, and Region |
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global community acquired bacterial pneumonia treatment market was valued at US$ 1503.3 million in 2021 and is expected to register a revenue CAGR of 6.6% to reach US$ 2672.1 million by 2030.
Market Fundamentals
Community acquired bacterial pneumonia is a type of pneumonia that develops outside of hospitals or healthcare settings. It is a common condition that occurs when bacteria infect the lungs, causing inflammation and the accumulation of fluid in the air sacs of the lungs. The most common bacteria that cause community acquired bacterial pneumonia include Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumonia. Symptoms of community acquired bacterial pneumonia typically include coughing, fever, chest pain, shortness of breath, fatigue, and chills. The severity of symptoms can vary depending on the individual and the type of bacteria causing the infection.
Diagnosis of community acquired bacterial pneumonia involves a physical examination, medical history review, and tests such as a chest X-ray, blood tests, and sputum culture. Treatment usually involves a course of antibiotics to target the specific bacteria causing the infection. In severe cases, hospitalization may be necessary for intravenous antibiotics and supportive care. Prevention of community acquired bacterial pneumonia includes practicing good hygiene, such as washing hands frequently, avoiding close contact with sick individuals, and getting vaccinated against the flu and pneumonia.
Community-acquired bacterial pneumonia is usually treated with antibiotics to target the specific bacteria causing the infection. The choice of antibiotics depends on several factors, including the severity of the infection, the patient's age and health status, and the prevalence of antibiotic resistance in the community.
[6575755]
Market Dynamics
The global prevalence of community acquired bacterial pneumonia is on the rise due to various factors such as the aging population, smoking, and environmental pollution. For instance, according to the Centers For Diseases Control And Prevention article of November 2022, the U.S. has about 40 million smokers, and half a million Americans die prematurely of smoking or exposure to secondhand smoke. With the rise of antibiotic-resistant bacteria, there is an urgent need for the development of new antibiotics that are effective against these pathogens. This has led to a surge in research & development activities in the field of antibacterial drugs, which is expected to drive the growth of the global community acquired bacterial pneumonia treatment market. Additionally, surging in drug approvals, launches, and pipeline drugs is also resulting in the growth of the global community acquired bacterial pneumonia treatment market. The growing awareness about the severity of community acquired bacterial pneumonia and its complications is expected to increase the demand for its treatment.
Additionally, the increasing awareness among healthcare professionals about the proper diagnosis and treatment of community acquired bacterial pneumonia is expected to boost the growth of the global community acquired bacterial pneumonia treatment market. Moreover, various governments across the world are investing in research and development activities for the development of new antibiotics and are also taking initiatives to promote the proper diagnosis and treatment of community acquired bacterial pneumonia. These initiatives and funding are expected to drive the growth of the global community acquired bacterial pneumonia treatment market. However, high costs associated with research & development, shortage of skilled professionals and lack of healthcare infrastructure in developing economies are some of the restraints impeding the overall market growth.
Market Ecosystem
The global community acquired bacterial pneumonia treatment market is analyzed from four perspectives: Treatment Type, Route of administration, Distribution Channel, and Region.
Community Acquired Bacterial Pneumonia Treatment Market by Treatment Type
[856756]
Based on the treatment type, the global community acquired bacterial pneumonia treatment market is segmented into antibiotics, antivirals, and others.
The antibiotics segment dominated the market with the principal revenue share in 2021, as antibiotics are used as first-line agents in treating community acquired bacterial pneumonia. The increasing prevalence of drug-resistant strains of bacteria, has led to the development of new antibiotics and combination therapies. Additionally, there are several classes of antibiotics available for the treatment of community acquired bacterial pneumonia, including macrolides, fluoroquinolones, penicillin’s, cephalosporins, and others. The availability of a wide range of antibiotics has increased the options available to healthcare providers for the treatment of community acquired bacterial pneumonia. Moreover, the significant progress in the development of new antibiotics, including novel mechanisms of action and improved pharmacokinetic properties. This has increased the efficacy and safety of antibiotics and has driven the growth of the antibiotics segment in the community acquired bacterial pneumonia treatment market.
Community Acquired Bacterial Pneumonia Treatment Market by Route of Administration
Based on the route of administration, the global community acquired bacterial pneumonia treatment market is bifurcated into oral and intravenous.
The oral route segment dominated the market with the largest revenue share in 2021, attributed to patient choice, the availability of effective oral antibiotics, and a lower risk of sequelae were all factors.Many patients prefer oral medications over other routes of administration, such as injections or intravenous infusions. Oral medications are generally more convenient and less invasive, which can lead to better patient compliance. Additionally, there are several effective oral antibiotics available for the treatment of community acquired bacterial pneumonia, such as macrolides, penicillin’s, and fluoroquinolones. These antibiotics can be used to treat mild to moderate cases of community acquired bacterial pneumonia. Many patients with mild to moderate community acquired bacterial pneumonia can be treated on an outpatient basis with oral antibiotics. This can reduce the burden on hospitals and healthcare systems. These overall factors contribute to the growth of the oral route segment.
Community Acquired Bacterial Pneumonia Treatment Market by Distribution Channel
Based on the distribution channel, the global community acquired bacterial pneumonia treatment market is segmented into hospital, retail, and online pharmacy.
The hospital pharmacy segment dominated the market with the largest revenue share in 2021, owing to the large footfall of patients. Hospital pharmacies have access to specialized healthcare professionals, such as infectious disease specialists, who can provide expert advice on the appropriate use of antibiotics for the treatment of community acquired bacterial pneumonia. Many patients with severe cases of community acquired bacterial pneumonia require hospitalization and inpatient treatment. Hospital pharmacies are equipped to provide the necessary medications and supportive therapies for these patients. Hospital pharmacies often have centralized ordering and distribution systems, which can improve the efficiency and accuracy of medication administration for community acquired bacterial pneumonia patients. These overarching variables contribute to the hospital pharmacy segment growth.
Community Acquired Bacterial Pneumonia Treatment Market by Region
Geographically, the global community acquired bacterial pneumonia treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global community acquired bacterial pneumonia treatment market with the largest revenue share in 2021, attributed to increasing research & development activities, rising healthcare expenditure, and the presence of major key players. Additionally, companies across the region are continuously working on launching new and novel medication for the treatment of community acquired bacterial pneumonia which is also helping in the growth of the regional market. For instance, In November 2022, Eagle Pharmaceuticals, Inc. announced that the FDA had accepted its investigational new drug ("IND") application for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the adjuvant treatment of severe community-acquired bacterial pneumonia. The Phase 2 research will enrol about 276 patients with severe community-acquired pneumonia at around 120 locations worldwide as early as the beginning of 2023.
Competitive Landscape
The prominent players operating in the global community acquired bacterial pneumonia treatment market are:
Strategic Developments
The estimated market size of the global community acquired bacterial pneumonia treatment market in 2030 is US$ 2672.1 million.
The CAGR of the community acquired bacterial pneumonia treatment market during the forecast period will be 6.6% from 2022 to 2030.
The development of new antibiotics surging in drug approvals & launches and the rising prevalence of community acquired bacterial pneumonia are factors driving the growth of the global community acquired bacterial pneumonia treatment market.
The costs associated with research & development, shortage of skilled professionals, and lack of healthcare infrastructure in developing economies are factors restricting the global market growth to full potential.
Some prominent players operating in the global community acquired bacterial pneumonia treatment market are Nabriva Therapeutics plc, Cumberland Pharmaceuticals Inc., Paratek Pharmaceuticals, Inc., Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, and Allergan Shionogi Inc. among others.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.